首页> 美国卫生研究院文献>Journal of Translational Medicine >Intra-discal injection of autologous hypoxic cultured bone marrow-derived mesenchymal stem cells in five patients with chronic lower back pain: a long-term safety and feasibility study
【2h】

Intra-discal injection of autologous hypoxic cultured bone marrow-derived mesenchymal stem cells in five patients with chronic lower back pain: a long-term safety and feasibility study

机译:自体低氧培养的骨髓间充质干细胞的椎间盘内注射治疗5例慢性下腰痛患者:长期安全性和可行性研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundChronic low back pain due to disc degeneration represents a major social and economic burden worldwide. The current standard of care is limited to symptomatic relief and no current approved therapy promotes disc regeneration. Bone marrow-derived mesenchymal stem cells (MSCs) are easily accessible and well characterized. These MSCs are multipotent and exhibit great tissue regenerative potential including bone, cartilage, and fibrous tissue regeneration. The use of this cell-based biologic for treating protruding disc herniation and/or intervertebral disc degeneration is a promising therapeutic strategy, due to their known regenerative, immuno-modulatory and anti-inflammatory properties.
机译:背景技术由于椎间盘退变而引起的慢性下背痛代表着全世界的主要社会和经济负担。当前的护理标准仅限于症状缓解,目前没有批准的疗法可促进椎间盘再生。骨髓来源的间充质干细胞(MSC)易于访问且特征明确。这些MSC具有多种功能,并具有巨大的组织再生潜力,包括骨骼,软骨和纤维组织再生。由于其已知的再生,免疫调节和抗炎特性,使用这种基于细胞的生物制剂治疗突出的椎间盘突出和/或椎间盘退变是一种有前途的治疗策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号